These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 33942843

  • 1. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.
    Geiersbach KB, Sill DR, Del Rosario KM, Meyer RG, Spears GM, Yuhas JA, Sukov WR, Jenkins RB, Ocal IT, Mounajjed T, Chen B.
    Am J Clin Pathol; 2021 Oct 13; 156(5):886-894. PubMed ID: 33942843
    [Abstract] [Full Text] [Related]

  • 2. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 13; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 3. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE, Marotti JD, Memoli VA, Wells WA, Tafe LJ.
    Am J Clin Pathol; 2015 Aug 13; 144(2):247-52. PubMed ID: 26185309
    [Abstract] [Full Text] [Related]

  • 4. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.
    Histopathology; 2017 May 13; 70(6):966-974. PubMed ID: 28032917
    [Abstract] [Full Text] [Related]

  • 5. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 13; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP, Wang K, Xu J, Chen J, Zhang YF, Wu HM, Zhang MH, Long XX, Luo XL, Zhang KP, Lin DY, Liu YH.
    Breast Cancer Res Treat; 2017 Dec 13; 166(3):757-764. PubMed ID: 28861637
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases.
    Zhang X, Bleiweiss I, Jaffer S, Nayak A.
    Clin Breast Cancer; 2017 Oct 13; 17(6):486-492. PubMed ID: 28433541
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z, Noske A.
    PLoS One; 2015 Oct 13; 10(10):e0140652. PubMed ID: 26473483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.